hsk31858
Small moleculeexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Oct 28, 2021 (NCT05023525)
Timeline
Indications
Mechanism of action
- Aminopeptidase NAALADL1INHIBITOR
NAALADL1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07134465 | Phase 1 | Aug 11, 2025 | Haisco Pharmaceutical |
| NCT06820749 | Phase 2 | Dec 10, 2024 | Haisco Pharmaceutical |
| NCT07134478 | Phase 1 | Oct 28, 2024 | Haisco Pharmaceutical |
| NCT06637254 | Phase 2 | Oct 22, 2024 | Haisco Pharmaceutical |
| NCT06660992 | Phase 3 | Sep 30, 2024 | Haisco Pharmaceutical |
| NCT06569784 | Phase 1 | May 30, 2024 | Haisco Pharmaceutical |
| NCT05601778 | Phase 2 | Dec 6, 2022 | Guangzhou Medical University, Haisco Pharmaceutical |
| NCT05663593 | Phase 1 | Feb 23, 2022 | Haisco Pharmaceutical, Peking University |
| NCT05023525 | Phase 1 | Oct 28, 2021 | Haisco Pharmaceutical, Nucleus Network Ltd |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Haisco Pharmaceutical | For profit | 9 | 9 | 3 | 2021 |
| Guangzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1